Research To Practice | Oncology Videos

Latest Episodes:

Colorectal Cancer — A Roundtable Discussion on the Use of Molecular Residual Disease Analysis Feb 26, 2026

Show notes

Featuring an interview with Dr Stacey A Cohen, Dr Arvind Dasari and Dr Christopher Lieu, including the following topics:

Biological Principles Underlying Circulating Tumor DNA (ctDNA) Molecular Residual Disease (MRD) Testing in Colorectal Cancer (CRC) — Dr Cohen (0:00)
Potential Utility of ctDNA Testing to Identify Patients with Localized CRC Who Might Benefit from Treatment De-escalation or Escalation — Dr Lieu (17:44)
Role of ctDNA Analysis in the Management of Metastatic CRC – Dr Dasari (36:16)
Clinical Investigator Survey Results (56:06)
Case: A woman in her early 40s with mismatch repair-proficient/microsatellite-stable (MSS), low-risk Stage II colon cancer — Dr Lieu (1:23:05)
Case: A woman in her early 70s with microsatellite instability-high Stage III colon cancer with a BRAF mutation — Dr Cohen (1:26:06)
Case: A man in his mid 40s with metastatic CRC — Dr Dasari (1:31:57)
Case: A man in his early 50s with low-risk Stage III colon cancer — Dr Lieu (1:37:54)
Case: A man in his early 30s with MSS, high-risk Stage II CRC — Dr Cohen (1:50:17)
Case: A woman in her early 50s with metastatic CRC — Dr Dasari (1:52:05)
Case: A man in his early 60s with Stage IV colon cancer — Dr Lieu (1:56:05)

CME information and select publications

Urothelial Bladder Cancer — Microlearning Activity 2 with Dr Terence Friedlander: ESMO Congress 2025 Review Feb 23, 2026

Show notes

Featuring an interview with Dr Terence Friedlander, including the following topics:

Perioperative durvalumab with neoadjuvant chemotherapy: Health-related quality-of-life outcomes in the NIAGARA trial (0:00)
Targeting HER2 in locally advanced or metastatic urothelial carcinoma (5:17)
TROP2-targeted antibody-drug conjugates for locally advanced or metastatic urothelial carcinoma (18:19)

CME information and select publications

Multiple Myeloma: Inside the Issue of Cereblon E3 Ligase Modulators Feb 18, 2026

Show notes

Featuring perspectives from Dr Natalie S Callander and Dr Paul G Richardson, including the following topics:

Introduction: Clinical Trials We LOVE to Discuss (0:00)
Mechanism of Action of Cereblon E3 Ligase Modulators (CELMoDs) (8:42)
Available Efficacy Data with CELMoDs in the Management of Relapsed/Refractory Multiple Myeloma (MM) (15:59)
Extramedullary Disease (19:23)
Spectrum and Management of CELMoD-Associated Adverse Events (30:12)
Ongoing Phase II and III Trials Evaluating CELMoDs for MM (34:53)

CME information and select publications

Metastatic Bladder Cancer — Rapid Case Review Issue 2 Feb 17, 2026

Show notes

Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics:

Case: A man in his early 60s with urothelial bladder cancer (UBC) is found to have metastatic disease shortly after surgery (0:00)
Case: A man in his late 70s experiences disease progression after first- and second-line treatment for metastatic disease (7:39)
Case: A fit man in his early 70s presents with metastatic disease (15:22)

CME information and select publications

Gynecologic Cancers — Highlights from the 2025 ESMO Annual Meeting Feb 16, 2026

Show notes

Featuring perspectives from Dr Terence Friedlander and Dr Rana R McKay, including the following topics:

Introduction (0:00)
Up-Front Treatment of Ovarian Cancer (OC) (1:13)
Management of Platinum-Resistant OC (11:49)
Up-Front Management of Metastatic Endometrial Cancer (32:42)
Management of HER2-Positive Gynecologic Cancers (45:11)
Management of Cervical Cancer (53:10)

CME information and select publications

Relapsed/Refractory Multiple Myeloma — Microlearning Activity 2 with Dr Sagar Lonial: ASH 2025 Review Feb 13, 2026

Show notes

Featuring an interview with Dr Sagar Lonial, including the following topics:

Phase 3 randomized study evaluating teclistamab and daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib for patients with relapsed/refractory (R/R) multiple myeloma (MM) (0:00)
Management of belantamab mafodotin-associated ocular events with dose modifications guided by standard assessments (3:15)
Belantamab mafodotin in combination with bortezomib, lenalidomide and dexamethasone for transplant-ineligible patients with newly diagnosed MM (8:00)
Other investigational strategies for R/R MM (12:55)

CME information and select publications

Squamous Cell Carcinoma of the Anal Canal — An Interview with Dr Marwan Fakih Feb 12, 2026

Show notes

Featuring an interview with Dr Marwan Fakih, including the following topics:

Etiology and incidence of squamous cell carcinoma of the anal canal (SCAC) (0:00)
Novel therapeutic strategies for the treatment of SCAC: Immunotherapy combinations and monitoring for recurrence with circulating tumor DNA assessment (4:37)
Perspectives on the overall survival benefit observed with first-line retifanlimab and carboplatin/paclitaxel; potential for cure for patients with SCAC (8:22)
Case: A woman in her mid 60s with recurrent unresectable metastatic SCAC receives retifanlimab with carboplatin/paclitaxel (16:56)
Case: A woman in her mid 60s with recurrent unresectable metastatic SCAC receives single-agent immunotherapy (25:22)
Case: A woman in her 60s with previously untreated metastatic SCAC receives chemotherapy and attains a complete response (29:21)
Future directions for the treatment of SCAC (33:22)

CME information and select publications

Squamous Cell Carcinoma of the Anal Canal — An Interview with Dr Marwan Fakih (Companion Faculty Lecture) Feb 11, 2026

Show notes

Featuring a slide presentation and related discussion from Dr Marwan Fakih, including the following topics:

Overview of etiology, incidence and staging of squamous cell cancer of the anal canal (SCAC) (0:00)
Systemic therapy approaches to the management of recurrent unresectable and metastatic SCAC (6:17)
Available data with anti-PD-1 (pembrolizumab, nivolumab, retifanlimab) and anti-CTLA-4 (ipilimumab) agents in the management of unresectable metastatic SCAC previously treated with chemotherapy (12:59)
Immunotherapy combined with chemotherapy for the front-line treatment of SCAC (20:48)
Efficacy and safety of retifanlimab combined with carboplatin/paclitaxel as first-line treatment for SCAC in the Phase III POD1UM-303 trial (23:43)

CME information and select publications

Prostate Cancer — Microlearning Activity 2 with Dr Rana R McKay: ESMO Congress 2025 Review Feb 10, 2026

Show notes

Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics:

EMBARK trial: Enzalutamide for biochemically recurrent prostate cancer (0:00)
Final results from the Phase III PRESTO study: Combined androgen blockade for high-risk biochemically relapsed prostate cancer (4:05)
Other novel treatment strategies for patients with metastatic prostate cancer (10:31)

CME information and select publications

Antibody-Drug Conjugates for Ovarian Cancer — An Interview with Dr Kathleen N Moore Feb 09, 2026

Show notes

Featuring an interview with Dr Kathleen N Moore, including the following topics:

Overview of the mechanism of action and pharmacology of antibody-drug conjugates (ADCs) (0:00)
Comparing toxicities of conventional chemotherapy and ADCs (6:26)
Potential of ADCs as maintenance therapy for ovarian cancer (11:35)
Treatment based on platinum sensitivity and homologous recombination-deficiency status (15:10)
Case: A woman in her mid 70s presenting with Stage IV ovarian cancer receives raludotatug deruxtecan (18:46)
Case: A woman in her mid 60s with relapsed/refractory ovarian cancer receives mirvetuximab soravtansine (41:22)
Case: A woman in her early 70s with relapsed/refractory ovarian cancer receives multiple ADCs in clinical trials (45:57)

CME information and select publications